Joyce Awujor
Psychiatric/Mental Health · Havre de Grace, MDNPI 1063119832
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 185 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 15.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,246, 3.9 times the $577 reported in 2023. Among psychiatric/mental health clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 185 payments — averaging $26.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$748
- AbbVie$687
- Otsuka America Pharmaceutical, Inc.$416
- Johnson & Johnson$381
- Lundbeck LLC$374
- Neurocrine Biosciences, Inc.$319
- plus $2K from 14 others
What the payments were for
- Food & beverage$4,846100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$461
- VRAYLAR$217
- Auvelity$121
- Austedo XR$100
- REXULTI$100
How this compares
$4,858 in reported general payments places this provider in the 95th percentile of 1,461 psychiatric/mental health providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 11 | $756 |
| Olanzapine | 16 | $495 |
| Hydroxyzine Hcl | 30 | $351 |
| Bupropion Hcl | 20 | $332 |
| Bupropion XlBupropion Hcl | 12 | $297 |
| Risperidone | 27 | $279 |
| Buspirone Hcl | 43 | $257 |
| Bupropion Hcl SrBupropion Hcl | 33 | $253 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 15 | $223 |
| Quetiapine Fumarate | 29 | $223 |
| Trazodone Hcl | 52 | $196 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 26 | $195 |
| Escitalopram Oxalate | 16 | $163 |
| Lamotrigine | 25 | $154 |
| Benztropine Mesylate | 17 | $145 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Havre de Grace
- Antonio HeroldHavre de Grace$23K
- Hara OyedejiOwings Mills$780K
- Ilya RozenbergGlen Burnie$572K
- Michelle WilliamsColumbia$158K
- Kristin ClemensGaithersburg$36K
- Paul KlaverweidenFruitland$17K
- Margaret WebbAberdeen$16K
- Susan KrausTowson$16K
- Anyinke AtabongRockville$15K
- Zenatsehay GebretsadikColumbia$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.